CSI Market
Sign In | Register

Agios Pharmaceuticals Inc (AGIO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AGIO Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Agios Pharmaceuticals Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-199.81
Depreciation & amortization2.71
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-2.77
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation31.48
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decreasein Collaboration Receivable Due from Related Parties Current-
Increase Decrease In Collaboration Receivable Due From Related Parties Current-
Increase Decrease In Collaboration Receivable Other Current-
Operating Lease Right Of Use Asset Amortization-
Operating Lease Right Of Use Asset Amortization Expense3.26
Gain Loss On Sale Of Contingent Payments-
Increase Decrease In Operating Lease Liability-4.46
Income taxes0.00
Realized Investment Gains (Losses), Total0.10
Increase (Decrease) in Accounts Receivable9.54
Increase (Decrease) in Accounts Payable-1.91
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-10.81
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets7.34
Other Working Capital0.15
Other Noncash Income (Expense)0.00
Other net2.27
Payments for (Proceeds from) Other Operating Activities-14.52
Discontinued operations0.00
Net Cash flow from Operating Activities-176.23
Investing Activities
Capital Expenditures-1.98
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities508.26
Payments to Acquire Available-for-sale Securities, Debt-299.75
Real Estate Investments0.00
Proceeds From Sale Of Contingent Payments-
Payments For Asset Acquisition-
Payments Associated With License Agreement-
Decrease in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-25.19
Discontinued operations0.00
Net Cash Flow from Investing Activities181.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock5.23
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Initial Public Offering And Private Placement-
Proceeds From Payments Of Issuance Of Common Stock Commissions And Offering Costs-
Reiumbursement Of Stock Issuance Costs-
Finance Lease Principal Payments-
Proceeds From Sale Of Future Revenues Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents89.13
Capital Expenditures Incurred But Not Yet Paid0.67
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.23
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-178.21
Total Cash Flow10.52
4 historic quarters locked

Sign in to unlock the full Agios Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Agios Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001439222-26-000118

Figures are derived from filed reports and may be restated. Historical data is subject to revision.